Dosing in children

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 3, 2010, Pages 367-370

  Holford, N ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DEXMEDETOMIDINE; MORPHINE; PANTOPRAZOLE; PARACETAMOL;

CHILD; CLINICAL PHARMACOLOGY; DOSE CALCULATION; DRUG CLEARANCE; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; SHORT SURVEY; STEADY STATE;

AGE FACTORS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; PEDIATRICS; PHARMACEUTICAL PREPARATIONS;

EID: 77149130496     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.262     Document Type: Short Survey

References (29)

1. Holford, N.H. The target concentration approach to Clinical drug development. Clin. Pharmacokinet. 29, 287-291 (1995).
2. Engle, W.A.; American academy of Pediatrics committee on Fetus and Newborn. age terminology during the perinatal period. Pediatrics 114, 1362-1364 (2004).
3. Tod, M., Jullien, V. & Pons, G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet. 47, 231-243 (2008).
4. Anderson, B.J. & Holford, N.H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25-36 (2009).
5. Anderson, B.J. & Holford, N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008).
6. Savage, V.M., Deeds, E.J. & Fontana, W. Sizing up allometric scaling theory. PLoS Comput. Biol. 4, e1000171 (2008).
7. Janmahasatian, S., Dufull, S.B., Ash, S., Ward, L.C., Byrne, N.M. & Green, B. Quantification of lean bodyweight. Clin. Pharmacokinet. 44, 1051-1065 (2005).
8. Rhodin, M.M. et al. human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24, 67-76 (2009).
9. Han, P.Y., Dufull, S.B., Kirkpatrick, c.M. & Green, B. Dosing in obesity: a simple solution to a big problem. Clin. Pharmacol. Ther. 82, 505-508 (2007).
10. Anand, K.J. et al.; NEOPaIN Trial Investigators Group. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPaIN trial. Br. J. Anaesth. 101, 680-689 (2008).
11. Potts, A.L., Anderson, B.J., Warman, G.R., Lerman, J., Diaz, S.M. & Vilo, S. Dexmedetomidine pharmacokinetics in pediatric intensive care-a pooled analysis. Paediatr. Anaesth. 19, 1119-1129 (2009).
12. Mukherjee, a., Dombi, T., Wittke, B. & Lalonde, R. Population pharmacokinetics of sildenafl in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin. Pharmacol. Ther. 85, 56-63 (2009).
13. Anderson, B.J., Woollard, G.A. & Holford, N.H. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br. J. Clin. Pharmacol. 50, 125-134 (2000).
14. Allegaert, K. et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br. J. Anaesth. 99, 864-870 (2007).
15. Knibbe C. Are children small adults: what can modeling ofer to (Clinical) practice? PaGE 18 (2009). abstract 1678 http://www.page-meeting. org/?abstract=1678.
16. Schwartz, G.J. et al. New equations to estimate GFR in children with cKD. J. Am. Soc. Nephrol. 20, 629-637 (2009).
17. Holford, N.H. Target concentration intervention: beyond Y2K. Br. J. Clin. Pharmacol. 48, 9-13 (1999).
18. Li, F., Nandy, P., chien, S., Noel, G.J. & Tornoe, c.W. Pharmacometrics-based dose selection of levofoxacin as a treatment for post-exposure inhalational anthrax in children. Antimicrob. Agents Chemother. (2009); e-pub ahead of print 26 October 2009.
19. Mouksassi, M.S., Marier, J.F., cyran, J. & Vinks, A.A. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin. Pharmacol. Ther. 86, 667-671 (2009).
20. Anderson, B.J., allegaert, K. & Holford, N.H. Population Clinical pharmacology of children: general principles. Eur. J. Pediatr. 165, 741-746 (2006). (Pubitemid 44440510)
21. Anderson, B.J., allegaert, K. & Holford, N.H. Population Clinical pharmacology of children: modelling covariate efects. Eur. J. Pediatr. 165, 819-829 (2006). (Pubitemid 44627767)
22. Anderson, B.J., Woollard, G.A. & Holford, N.H. Acetaminophen analgesia in children: placebo efect and pain resolution after tonsillectomy. Eur. J. Clin. Pharmacol. 57, 559-569 (2001).
23. Holford, N.H. a size standard for pharmacokinetics. Clin. Pharmacokinet. 30, 329-332 (1996).
24. Anderson, B.J., McKee, A.D. & Holford, N.H. Size, myths and the Clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33, 313-327 (1997).
25. Pettersen, G. et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Br. J. Clin. Pharmacol. 67, 216-227 (2009).
26. US Food and Drug administration. Guidance for Industry: General considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products (1998).
27. Manolis, E. & Pons, G. Proposals for model based paediatric medicinal development within the current EU regulatory framework. Br. J. Clin. Pharmacol. 68, 493-501 (2009).
28. US Food and Drug administration. Guidance for Industry: Qualifying for Pediatric Exclusivity Under Section 505a of the Federal Food, Drug, and cosmetic act (1999).
29. Avramis, V.I. & Spence, S.A. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric aLL patients. J. Pediatr. Hematol. Oncol. 29, 239-247 (2007).